Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
GMP-ACAH37 | Human | GMP Human Activin A / INHBA Protein | |||
ACA-H5314 | Human | Human Activin A / INHBA Protein, premium grade |
|
||
ACA-H421b | Human | Human Activin A / INHBA Protein, Tag Free |
|
||
ACA-H424x | Human | Human Latent Activin A / INHBA Protein, His Tag |
|
Human Activin A Protein, premium grade (Cat. No. ACA-H5314) stimulates Human Activin RIl (Luc) HEK293 Reporter Cell. The specific activity of Human Activin A Protein, premium grade is>5.00 x 10^2 IU/mg, which is calibrated against WHO Reference Reagent Activin A (Human, Recombinant) NIBSC code: 91/626 (QC tested).
Human Activin A Protein, Tag Free (Cat. No. ACA-H421b) inhibits the proliferation of MPC-11 cells. The specific activity of Human Activin A Protein, Tag Free is > 5.00×10^2 IU/mg, which is calibrated against WHO Reference Reagent Activin A (Human, Recombinant) NIBSC code: 91/626 (Routinely tested).
Human Activin RIIB, His Tag (Cat. No. ACB-H5226) immobilized on CM5 Chip can bind Human Activin A Protein, Tag Free (Cat. No. ACA-H421b) with an affinity constant of 0.216 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Momelotinib Dihydrochloride | CYT-387; GS-0387; GSK-3070785 | Approved | Ojjaara, Omjjara | United States | Primary Myelofibrosis; Anemia | Glaxosmithkline Llc, Glaxosmithkline Plc | 2023-09-15 | Polycythemia; Polycythemia Vera; Anemia; Neoplasms; Myeloproliferative Disorders; Pancreatic Intraductal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Splenomegaly; Thrombocythemia, Essential; Carcinoma, Non-Small-Cell Lung | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
BLU-782 | BLU-782; IPN-60130 | Phase 2 Clinical | Blueprint Medicines Corp, Ipsen SA | Myositis Ossificans | Details |
Zilurgisertib | INCB-000928; INCB-00928 | Phase 2 Clinical | Incyte Corp | Anemia; Polycythemia Vera; Myelodysplastic Syndromes; Kidney Diseases; Ossification, Heterotopic; Multiple Myeloma; Myositis Ossificans; Primary Myelofibrosis; Thrombocythemia, Essential | Details |
KER-047 | KER-047 | Phase 1 Clinical | National Center For Advancing Translational Sciences | Anemia, Iron-Deficiency; Myositis Ossificans | Details |
Itacnosertib | TP-0184 | Phase 1 Clinical | Tolero Pharmaceuticals Inc, Sumitomo Dainippon | Solid tumours; Anemia | Details |
BCX-9250 | BCX-9250 | Phase 1 Clinical | Biocryst Pharmaceuticals Inc | Myositis Ossificans | Details |
This web search service is supported by Google Inc.